Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | USP8 | P40818 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.39 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080297 | 0.85 | KMT2A (0.46) | HDAC2 | |
| SCHEMBL7052347 | 0.84 | HDAC1 (0.40) | ACLYMCL1 | |
| SCHEMBL7049830 | 0.83 | HDAC1 (0.38) | ACLYHDAC2 | |
| SCHEMBL7052305 | 0.81 | HDAC8 (0.35) | ACLYMCL1 | |
| SCHEMBL7050676 | 0.79 | HDAC8 (0.34) | ACLYMCL1 | |
| SCHEMBL7076566 | 0.78 | BCL2L1 (0.55) | BCL2L1MCL1NR1H4 | |
| SCHEMBL7049821 | 0.76 | HDAC1 (0.34) | ACLY | |
| SCHEMBL7076342 | 0.76 | PTGES (0.60) | BCL2L1MCL1HDAC2RXFP1PTGS1 | |
| SCHEMBL7081192 | 0.75 | PTGS1 (0.51) | HDAC2RXFP1PTGES2PTGS1 | |
| SCHEMBL7081195 | 0.75 | PTGS1 (0.51) | HDAC2RXFP1PTGES2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | ACLY 181/4885BCL2L1 1792/4885MCL1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.